Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term UT-15C SR continuation study in pulmonary arterial hypertension
ACTRN12606000187549Phase 3Not yet recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of TransCon treprostinil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by United Therapeutics Corporation. Primary endpoints: Long-term clinical improvement assessment and Long-term drug tolerability. Planned start Nov 2006; status: not yet recruiting.
02
Drugs
TransCon treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on ACTRN12606000187549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000187549.